AI Article Synopsis
Article Abstract
Introduction: Fibroblast growth factor inhibitors (FGFRi) are novel cancer drugs that offer new hope for patients with advanced biliary tract cancers and metastatic urothelial tumors. Despite their effectiveness, they often cause hyperphosphatemia.
Materials And Methods: We investigated the incidence and characteristics of hyperphosphatemia in patients treated with FGFRi at Northwell Health, comparing findings with clinical trials and the FDA Adverse Event Reporting System database.
Results: 94% of patients in our series developed hyperphosphatemia, predominantly grade 2. The time-to-onset of hyperphosphatemia was longer than noted in clinical trials. Patients on erdafitinib showed a higher-than-expected incidence and grade of hyperphosphatemia.
Conclusion: Collaboration between nephrologists and oncologists is crucial for optimizing treatment benefits and managing side effects. Further research is warranted to refine management strategies and to understand the clinical implications of hyperphosphatemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5414/CN111488 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.
J Hematol Oncol
December 2024
Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Article Synopsis
- - Lenvatinib is a key treatment for hepatocellular carcinoma (HCC) that works by blocking critical growth factor receptors, which helps reduce tumor growth and improves immune response.
- - Although lenvatinib is effective on its own, drug resistance is a growing issue due to factors like genetic mutations and changes in the tumor environment.
- - Combining lenvatinib with immune checkpoint inhibitors could enhance treatment effectiveness, but challenges related to safety remain, highlighting the need for research on resistance mechanisms and biomarkers for better personalized therapies.
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study.
J Hepatol
December 2024
Phase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. Electronic address:
Background And Aims: Glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) are key regulators of glucose and lipid metabolism. In the present study, we assessed the safety and efficacy of a novel GLP-1/FGF21 dual agonist HEC88473 for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) combined with type 2 diabetes mellitus (T2DM).
Methods: This was a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase 1b/2a trial.
Green synthesis of magnesium oxide nanoparticles using the extract of to enhance the healing of burn wounds.
J Drug Target
December 2024
Department of Tissue Engineering, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Treating burn lesions has always been challenging because any product should be cheap, accessible, and have anti-bacterial commodities and tissue regeneration properties. The green synthesis of magnesium oxide nanoparticles (GS-MgONPs) can create an optimal prospect that is safe with low toxicity in biological tissue and better safety for application while including the antibacterial effect. This recent study aimed to evaluate the effectiveness of burn wound treatment using GS-MgONPs in rats.
View Article and Find Full Text PDFMelatonin Reduces Mito-Inflammation in Ischaemic Hippocampal HT22 Cells and Modulates the cGAS-STING Cytosolic DNA Sensing Pathway and FGF21 Release.
J Cell Mol Med
December 2024
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Mitochondrial dysfunction is a key event in many pathological conditions, including neurodegenerative processes. When mitochondria are damaged, they release damage-associated molecular patterns (DAMPs) that activate mito-inflammation. The present study assessed mito-inflammation after in vitro oxygen-glucose deprivation as a representation of ischaemia, followed by reoxygenation (OGD/R) of HT22 cells and modulation of the inflammatory response by melatonin.
View Article and Find Full Text PDFC3 cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-κB signaling pathway.
J Transl Med
December 2024
Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Gastric cancer (GC) remains one of the most lethal malignancies globally, with limited therapeutic options. Cancer-associated fibroblasts (CAFs), a diverse population of stromal cells within the tumor microenvironment (TME), play a central role in tumor progression and therapeutic resistance. However, the specific markers identifying tumor-promoting CAF subsets in GC have yet to be fully characterized.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!